

Supplementary Appendix 6: SARS-CoV-2 IgG spike, RBD, and NP antibody response following mRNA-1273 or BNT162b2 vaccination in hemodialysis patients stratified by patients on immunosuppressive medication, prior solid-organ transplant, versus no additional comorbidity.

Note: NP=nucleocapsid protein, RBD=receptor binding domain.

Note: Hemodialysis patients received either the mRNA-1273 or the BNT162b2 vaccine. Serologic assessments were conducted at multiple dilutions and the 0.00625 dilution is represented.

Note: Sample sizes for mRNA-1273 at 6-7 weeks were as follows: no additional status (n=56), immunosuppression (n=5). Sample sizes for BNT162b2 at 6-7 weeks were as follows: no additional status (n=66), immunosuppression (n=4). Sample sizes for mRNA-1273 at 12 weeks were as follows: no additional status (n=49), solid-organ transplant (n=18) immunosuppression (n=4). Sample sizes for BNT162b2 at 12 weeks were as follows: no additional status (n=111), solid-organ transplant (n=5), immunosuppression (n=6).

Note: Prior solid-organ transplant is not shown at 6-7 weeks as there were no transplant patients in the BNT162b2 cohort at this time point

Note: Dots represent individual serum samples collected at 6-7 weeks and 12 weeks post two-dose vaccination. Individuals with prior RT-PCR confirmed SARS-CoV-2 infection are indicated in green.

Note: Antibody levels are reported as relative ratios to synthetic standards. Seroconversion threshold represents a positive test and are 0.19, 0.186, and 0.396 for anti-spike, anti-RBD, anti-NP antibodies, respectively and is indicated by the dashed line for each antibody. Median antibody levels for each antigen are indicated by the red line.

Note: The median level of antigen in convalescent serum is from a cohort of 211 patients in the general population with prior COVID-19 of all severities represents a robust antibody response: 1.38, 1.25, and 1.13 for anti-spike, anti-RBD, and anti-NP antibodies, respectively and is indicated by the green line for each antibody.